相关临床试验
1258
233 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1757
进行中（未招募）
179
14.2%
已完成
598
47.5%
Enrolling By Invitation
13
1.0%
尚未招募
41
3.3%
招募中
238
18.9%
暂停
2
0.2%
终止
36
2.9%
Unknown
130
10.3%
撤回
21
1.7%
暂无批准数据
- A genome-wide study in Danish blood donor and patient cohorts maps the genetic architecture of cytokine autoantibodies and their links to common disease risk. - The research leverages the DBDS and CHB cohorts, supported by Bio- and Genome Bank Denmark and the Novo Nordisk Foundation. - Findings may clarify how naturally occurring anti-cytokine antibodies influence susceptibility to inflammatory and other common conditions. - The work was conducted with infrastructure from Rigshospitalet, Copenhagen University Hospital, and the Department of Clinical Immunology.
A groundbreaking clinical trial is investigating three different treatment approaches for intermediate-high risk pulmonary embolism (PE): standard heparin therapy, low-dose thrombolysis, and ultrasound-assisted thrombolysis (USAT). The study aims to enroll 210 patients and will evaluate the effectiveness of these interventions using refined Miller scores to measure thrombus reduction.
- Glofitamab combined with polatuzumab vedotin shows high response rates and durable remissions in heavily pretreated relapsed/refractory large B-cell lymphoma (LBCL). - The combination demonstrates benefits across histologies, including high-grade B-cell lymphomas and those who failed previous CAR T-cell therapy. - The overall response rate was 80.6%, with a complete response rate of 62.0%, and a median duration of complete response of 37.8 months. - Combining glofitamab with salvage chemoimmunotherapy is safe and effective for patients with R/R DLBCL who are eligible for autologous stem cell transplant (ASCT) or CAR T-cell therapy.
- The phase 3 RUBY trial demonstrated that dostarlimab combined with carboplatin and paclitaxel significantly improved progression-free survival and overall survival in patients with advanced or recurrent endometrial cancer across multiple molecular subgroups. - Patients with dMMR/MSI-H tumors showed the most dramatic benefit, with progression-free survival rates of 57.0% versus 10.2% in the placebo arm and overall survival rates of 83.3% versus 58.7%. - The TP53 mutation subgroup also demonstrated significant clinical benefit, with progression-free survival rates of 32.4% versus 17.8% and overall survival rates of 70.8% versus 33.2% in the placebo arm. - These findings support dostarlimab plus carboplatin/paclitaxel as a new standard of care for patients with newly diagnosed primary advanced or recurrent endometrial cancer.
